表紙
市場調查報告書

自體細胞療法的全球市場:2020年∼2024年

Global Autologous Cell Therapy Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 513918
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
自體細胞療法的全球市場:2020年∼2024年 Global Autologous Cell Therapy Market 2020-2024
出版日期: 2020年03月17日內容資訊: 英文 120 Pages
簡介

全球自體細胞療法市場在2020年∼2024年的預測期間內,預計將以22%的年複合成長率增長,達到19億7,000萬美元的規模。對治療心臟病和退行性疾病的有效藥物的需求增加成為主要的市場成長要素。此外傳統器官移植的限制,可望進一步促進市場的成長。

本報告提供全球自體細胞療法市場相關調查分析,提供市場規模及成長率,市場趨勢,推動市場要素,課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模:2019年
  • 市場預測:2019-2024年的預測

波特的五力分析

其他市場區隔

  • 市場區隔
  • 各治療法比較:市場規模與預測2019-2024
  • 自體幹細胞療法
  • 自體細胞免疫療法
  • 各治療法市場機會

客戶形勢

  • 概要

各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模與預測2019-2024
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲地區
  • 主要國家
  • 地區的市場機會

成長要素,課題,及趨勢

  • 市場成長要素
  • 交易量的成長要素-需求主導型成長
  • 交易量的成長要素-供給主導型成長
  • 交易量的成長要素-外部要素
  • 交易量的成長要素-需求轉移到鄰近市場
  • 價格上升要素-通貨膨脹
  • 價格成長要素-從低價格單位轉變到高價格單位
  • 市場課題
  • 市場趨勢

業者情勢

  • 概要
  • 形勢的創新
  • 供應商分析

交易廠商

  • 供應商的市場定位
  • Bayer AG
  • Brainstorm Cell Therapeutics Inc.
  • 第一三共
  • FUJIFILM HOLDINGS CORPORATION
  • Holostem Terapie Avanzate Srl
  • Osiris Therapeutics Inc.
  • 武田藥品工業
  • Teva Pharmaceutical Industries Ltd.
  • 住友化學
  • Vericel Corp.

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR41330

Technavio has been monitoring the global autologous cell therapy market 2020-2024 and it is poised to grow by USD 1.97 bn during 2020-2024, progressing at a CAGR of 22% during the forecast period. Our reports on global autologous cell therapy market 2020-2024 provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing demand for effective drugs for cardiac and degenerative disorders. In addition, limitations in traditional organ transplantations fueling demand for stem cell therapies is anticipated to boost the growth of the global autologous cell therapy market 2020-2024 as well.

Market Segmentation

Technavio's ‘ global autologous cell therapy market 2020-2024 ’ is segmented as below:

Therapy:

  • Autologous Stem Cell Therapy
  • Autologus Cellular Immunotherapies

Application:

  • Oncology
  • Musculoskeletal Disorders
  • Dermatology

Geographic segmentation

  • North America
  • APAC
  • Europe
  • South America
  • MEA

Key Trends for global autologous cell therapy market 2020-2024 growth

This study identifies limitations in traditional organ transplantations fueling demand for stem cell therapies as the prime reasons driving the global autologous cell therapy market 2020-2024 growth during the next few years.

Prominent vendors in global autologous cell therapy market 2020-2024

We provide a detailed analysis of around 25 vendors operating in the global autologous cell therapy market 2020-2024, including some of the vendors such as Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., FUJIFILM Holdings Corp., Holostem Terapie Avanzate Srl, Osiris Therapeutics Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Sumitomo Chemical Co. Ltd. and Vericel Corp. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Other 1

  • Market segments
  • Comparison by Other1 placement
  • Autologous stem cell therapy - Market size and forecast 2019-2024
  • Autologous cellular immunotherapies - Market size and forecast 2019-2024
  • Market opportunity by Other1

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • South America - Market size and forecast 2019-2024
  • MEA - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher-priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption
  • Vendor Analysis

Vendors covered

  • Market positioning of vendors
  • Bayer AG
  • Brainstorm Cell Therapeutics Inc.
  • Daiichi Sankyo Co. Ltd.
  • FUJIFILM Holdings Corp.
  • Holostem Terapie Avanzate Srl
  • Osiris Therapeutics Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sumitomo Chemical Co. Ltd.
  • Vericel Corp.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits:

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 5
  • 5.Key Finding 6
  • 6.Key Finding 7
  • 7.Key Finding 8
  • 8.Market in focus
  • 10.Parent market
  • 13.Market characteristics
  • 15.Offerings of vendors included in the market definition
  • 17.Market segments
  • 22.Global - Market size and forecast 2019 - 2024 ($ million)
  • 23.Global market: Year-over-year growth 2019 - 2024 (%)
  • 24.Five forces analysis 2019 & 2024
  • 26.Bargaining power of buyers
  • 27.Bargaining power of suppliers
  • 28.Threat of new entrants
  • 29.Threat of substitutes
  • 30.Threat of rivalry
  • 32.Market condition - Five forces 2019
  • 33.Other1 placement - Market share 2019-2024 (%)
  • 34.Comparison by Other1 placement
  • 35.Autologous stem cell therapy - Market size and forecast 2019-2024 ($ million)
  • 36.Autologous stem cell therapy - Year-over-year growth 2019-2024 (%)
  • 37.Autologous cellular immunotherapies - Market size and forecast 2019-2024 ($ million)
  • 38.Autologous cellular immunotherapies - Year-over-year growth 2019-2024 (%)
  • 39. Market opportunity by Other1
  • 40.Customer landscape
  • 41.Market share by geography 2019-2024 (%)
  • 42.Geographic comparison
  • 44.North America - Market size and forecast 2019-2024 ($ million)
  • 45.North America - Year-over-year growth 2019-2024 (%)
  • 47.Europe - Market size and forecast 2019-2024 ($ million)
  • 48.Europe - Year-over-year growth 2019-2024 (%)
  • 50.APAC - Market size and forecast 2019-2024 ($ million)
  • 51.APAC - Year-over-year growth 2019-2024 (%)
  • 53.South America - Market size and forecast 2019-2024 ($ million)
  • 54.South America - Year-over-year growth 2019-2024 (%)
  • 56.MEA - Market size and forecast 2019-2024 ($ million)
  • 57.MEA - Year-over-year growth 2019-2024 (%)
  • 58.Key leading countries
  • 59.Market opportunity by geography ($ million)
  • 60.Impact of drivers and challenges
  • 61.Vendor landscape
  • 63.Landscape disruption
  • 65.Industry risks
  • 67.Vendors covered
  • 69.Market positioning of vendors
  • 71.Bayer AG - Overview
  • 72.Bayer AG - Business segments
  • 73.Bayer AG - Key offerings
  • 74.Bayer AG - Key customers
  • 75.Bayer AG - Segment focus
  • 77.Brainstorm Cell Therapeutics Inc. - Overview
  • 78.Brainstorm Cell Therapeutics Inc. - Product and service
  • 79.Brainstorm Cell Therapeutics Inc. - Key offerings
  • 80.Brainstorm Cell Therapeutics Inc. - Key customers
  • 81.Brainstorm Cell Therapeutics Inc. - Segment focus
  • 83.Daiichi Sankyo Co. Ltd. - Overview
  • 84.Daiichi Sankyo Co. Ltd. - Business segments
  • 85.Daiichi Sankyo Co. Ltd. - Key offerings
  • 86.Daiichi Sankyo Co. Ltd. - Key customers
  • 87.Daiichi Sankyo Co. Ltd. - Segment focus
  • 89.FUJIFILM Holdings Corp. - Overview
  • 90.FUJIFILM Holdings Corp. - Business segments
  • 91.FUJIFILM Holdings Corp. - Key offerings
  • 92.FUJIFILM Holdings Corp. - Key customers
  • 93.FUJIFILM Holdings Corp. - Segment focus
  • 95.Holostem Terapie Avanzate Srl - Overview
  • 96.Holostem Terapie Avanzate Srl - Product and service
  • 97.Holostem Terapie Avanzate Srl - Key offerings
  • 98.Holostem Terapie Avanzate Srl - Key customers
  • 99.Holostem Terapie Avanzate Srl - Segment focus
  • 101.Osiris Therapeutics Inc. - Overview
  • 102.Osiris Therapeutics Inc. - Product and service
  • 103.Osiris Therapeutics Inc. - Key offerings
  • 104.Osiris Therapeutics Inc. - Key customers
  • 105.Osiris Therapeutics Inc. - Segment focus
  • 107.Takeda Pharmaceutical Co. Ltd. - Overview
  • 108.Takeda Pharmaceutical Co. Ltd. - Product and service
  • 109.Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 110.Takeda Pharmaceutical Co. Ltd. - Key customers
  • 111.Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 113.Teva Pharmaceutical Industries Ltd. - Overview
  • 114.Teva Pharmaceutical Industries Ltd. - Business segments
  • 115.Teva Pharmaceutical Industries Ltd. - Key offerings
  • 116.Teva Pharmaceutical Industries Ltd. - Key customers
  • 117.Teva Pharmaceutical Industries Ltd. - Segment focus
  • 119.Sumitomo Chemical Co. Ltd. - Overview
  • 120.Sumitomo Chemical Co. Ltd. - Business segments
  • 121.Sumitomo Chemical Co. Ltd. - Key offerings
  • 122.Sumitomo Chemical Co. Ltd. - Key customers
  • 123.Sumitomo Chemical Co. Ltd. - Segment focus
  • 125.Vericel Corp. - Overview
  • 126.Vericel Corp. - Product and service
  • 127.Vericel Corp. - Key offerings
  • 128.Vericel Corp. - Key customers
  • 129.Vericel Corp. - Segment focus
  • 131.Currency conversion rates for US$
  • 132.Research Methodology
  • 133.Validation techniques employed for market sizing
  • 134.Information sources
  • 135. List of abbreviations